Forest CEO: Aptalis a `Compelling Opportunity'

Jan. 8 (Bloomberg) -- Brent Saunders, chief executive officer of Forest Laboratories Inc., talks about the company's agreement to acquire Aptalis Pharma for $2.9 billion in cash. Aptalis is a closely held company whose shareholders include investment firm TPG Capital. Saunders speaks with Betty Liu on Bloomberg Television's "In the Loop." (Source: Bloomberg)
Russia Managing to Avoid GDP Growth Collapse: Kalen
40:05 - Phoenix Kalen, emerging markets strategist at Societe Generale, examines the Russian economy and the risks that may push the nation into recession. She speaks with Bloomberg’s Anna Edwards on “On The Move.” (Source: Bloomberg)
  • Asos's Large-Scale Investment Hurts Margins: Vidyaserkar
  • EU Can’t Set Exit Precedent With Greece: Bill Street
  • Can European Stocks Extend Rally Into Second Quarter?